{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:18:31Z","timestamp":1772065111931,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Direct reversion of cancers into normal-like tissues is an ideal strategy for cancer treatment. Recent reports have showed that defined transcription factors can induce reprogramming of cancer cells into pluripotent stem cells, supporting this notion. Here, we have developed a reprogramming method that uses a conceptually unique strategy for breast cancer cell treatment. We have screened a kinase inhibitor library and found that Rho-associated protein kinase (ROCK) and mammalian target of rapamycin (mTOR) kinase inhibitors can substitute for all transcription factors to be sufficient to reprogram breast cancer cells into progenitor cells. Furthermore, ROCK\u2013mTOR inhibitors could reprogram breast cancer cells to another terminal lineage-adipogenic cells. Genome-wide transcriptional analysis shows that the induced fat-like cells have a profile different from breast cancer cells and similar to that of normal adipocytes. In vitro and in vivo tumorigenesis assays have shown that induced fat-like cells lose proliferation and tumorigenicity. Moreover, reprogramming treatment with ROCK\u2013mTOR inhibitors prevents breast cancer local recurrence in mice. Currently, ROCK\u2013mTOR inhibitors are already used as antitumor drugs in patients, thus, this reprogramming strategy has significant potential to move rapidly toward clinical trials for breast cancer treatment.<\/jats:p>","DOI":"10.1038\/s41419-018-1002-2","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T09:20:38Z","timestamp":1536657638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["RETRACTED ARTICLE: Identification of protein kinase inhibitors to reprogram breast cancer cells"],"prefix":"10.1038","volume":"9","author":[{"given":"Jie","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"1002_CR1","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861\u2013872 (2007).","journal-title":"Cell"},{"key":"1002_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/cr.2011.28","volume":"21","author":"B Papp","year":"2011","unstructured":"Papp, B. & Plath, K. Reprogramming to pluripotency: stepwise resetting of the epigenetic landscape. Cell Res. 21, 486\u2013501 (2011).","journal-title":"Cell Res."},{"key":"1002_CR3","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.cell.2012.02.031","volume":"148","author":"AB Cherry","year":"2012","unstructured":"Cherry, A. B. & Daley, G. Q. Reprogramming cellular identity for regenerative medicine. Cell 148, 1110\u20131122 (2012).","journal-title":"Cell"},{"key":"1002_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00432-016-2258-5","volume":"143","author":"K Izgi","year":"2017","unstructured":"Izgi, K., Canatan, H. & Iskender, B. Current status in cancer cell reprogramming and its clinical implications. J. Cancer Res. Clin. Oncol. 143, 371\u2013383 (2017).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1002_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrc.2016.12","volume":"16","author":"S Powers","year":"2016","unstructured":"Powers, S. & Pollack, R. E. Inducing stable reversion to achieve cancer control. Nat. Rev. Cancer 16, 266\u2013270 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"1002_CR6","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1038\/onc.2012.349","volume":"32","author":"JY Lang","year":"2013","unstructured":"Lang, J. Y., Shi, Y. & Chin, Y. E. Reprogramming cancer cells: back to the future. Oncogene 32, 2247\u20132248 (2013).","journal-title":"Oncogene"},{"key":"1002_CR7","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1101\/gad.1213504","volume":"18","author":"K Hochedlinger","year":"2004","unstructured":"Hochedlinger, K. et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 18, 1875\u20131885 (2004).","journal-title":"Genes Dev."},{"key":"1002_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.molmed.2012.04.001","volume":"18","author":"V Ramos-Mejia","year":"2012","unstructured":"Ramos-Mejia, V., Fraga, M. F. & Menendez, P. iPSCs from cancer cells: challenges and opportunities. Trends Mol. Med. 18, 245\u2013247 (2012).","journal-title":"Trends Mol. Med."},{"key":"1002_CR9","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/onc.2012.237","volume":"32","author":"X Zhang","year":"2013","unstructured":"Zhang, X., Cruz, F. D., Terry, M., Remotti, F. & Matushansky, I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 32, 2249\u20132260 (2013). 2260.","journal-title":"Oncogene"},{"key":"1002_CR10","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1182\/blood-2009-07-231845","volume":"115","author":"JE Carette","year":"2010","unstructured":"Carette, J. E. et al. Generation of iPSCs from cultured human malignant cells. Blood 115, 4039\u20134042 (2010).","journal-title":"Blood"},{"key":"1002_CR11","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1242\/jcs.054783","volume":"122","author":"J Utikal","year":"2009","unstructured":"Utikal, J., Maherali, N., Kulalert, W. & Hochedlinger, K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J. Cell Sci. 122, 3502\u20133510 (2009).","journal-title":"J. Cell Sci."},{"key":"1002_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1073\/pnas.0912407107","volume":"107","author":"N Miyoshi","year":"2010","unstructured":"Miyoshi, N. et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc. Natl Acad. Sci. USA 107, 40\u201345 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1002_CR13","doi-asserted-by":"publisher","first-page":"e10320","DOI":"10.1371\/journal.pone.0010320","volume":"5","author":"G Chang","year":"2010","unstructured":"Chang, G. et al. Linking incomplete reprogramming to the improved pluripotency of murine embryonal carcinoma cell-derived pluripotent stem cells. PLoS ONE 5, e10320 (2010).","journal-title":"PLoS ONE"},{"key":"1002_CR14","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2011-03-340620","volume":"118","author":"SM Choi","year":"2011","unstructured":"Choi, S. M. et al. Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Blood 118, 1801\u20131805 (2011).","journal-title":"Blood"},{"key":"1002_CR15","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1182\/blood-2010-07-298331","volume":"117","author":"K Hu","year":"2011","unstructured":"Hu, K. et al. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood 117, e109\u2013e119 (2011).","journal-title":"Blood"},{"key":"1002_CR16","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1261\/rna.1162708","volume":"14","author":"SL Lin","year":"2008","unstructured":"Lin, S. L. et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 14, 2115\u20132124 (2008).","journal-title":"RNA"},{"key":"1002_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nm.2546","volume":"18","author":"R Amson","year":"2011","unstructured":"Amson, R. et al. Reciprocal repression between P53 and TCTP. Nat. Med. 18, 91\u201399 (2011).","journal-title":"Nat. Med."},{"key":"1002_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/CCO.0b013e32835b7d21","volume":"25","author":"R Amson","year":"2013","unstructured":"Amson, R., Karp, J. E. & Telerman, A. Lessons from tumor reversion for cancer treatment. Curr. Opin. Oncol. 25, 59\u201365 (2013).","journal-title":"Curr. Opin. Oncol."},{"key":"1002_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7351","volume":"6","author":"P Gascard","year":"2015","unstructured":"Gascard, P. et al. Epigenetic and transcriptional determinants of the human breast. Nat. Commun. 6, 6351 (2015).","journal-title":"Nat. Commun."},{"key":"1002_CR20","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/jcp.22450","volume":"226","author":"R Ho","year":"2011","unstructured":"Ho, R., Chronis, C. & Plath, K. Mechanistic insights into reprogramming to induced pluripotency. J. Cell. Physiol. 226, 868\u2013878 (2011).","journal-title":"J. Cell. Physiol."},{"key":"1002_CR21","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.neuron.2011.05.003","volume":"70","author":"SS Han","year":"2011","unstructured":"Han, S. S., Williams, L. A. & Eggan, K. C. Constructing and deconstructing stem cell models of neurological disease. Neuron 70, 626\u2013644 (2011).","journal-title":"Neuron"},{"key":"1002_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nature10761","volume":"481","author":"DA Robinton","year":"2012","unstructured":"Robinton, D. A. & Daley, G. Q. The promise of induced pluripotent stem cells in research and therapy. Nature 481, 295\u2013305 (2012).","journal-title":"Nature"},{"key":"1002_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5112","volume":"5","author":"CK Sun","year":"2014","unstructured":"Sun, C. K. et al. Senescence impairs direct conversion of human somatic cells to neurons. Nat. Commun. 5, 4112 (2014).","journal-title":"Nat. Commun."},{"key":"1002_CR24","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.celrep.2014.11.040","volume":"9","author":"D Zhou","year":"2014","unstructured":"Zhou, D. et al. Conversion of fibroblasts to neural cells by p53 depletion. Cell Rep. 9, 2034\u20132042 (2014).","journal-title":"Cell Rep."},{"key":"1002_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cell.2007.07.003","volume":"130","author":"M Collado","year":"2007","unstructured":"Collado, M., Blasco, M. A. & Serrano, M. Cellular senescence in cancer and aging. Cell 130, 223\u2013233 (2007).","journal-title":"Cell"},{"key":"1002_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000167806","volume":"122","author":"Q Yang","year":"2008","unstructured":"Yang, Q. Cellular senescence, telomere recombination and maintenance. Cytogenet. Genome Res. 122, 211\u2013218 (2008).","journal-title":"Cytogenet. Genome Res."},{"key":"1002_CR27","doi-asserted-by":"publisher","first-page":"11677","DOI":"10.1158\/0008-5472.CAN-07-1390","volume":"67","author":"Q Yang","year":"2007","unstructured":"Yang, Q. et al. Functional diversity of human protection of telomeres 1 isoforms in telomere protection and cellular senescence. Cancer Res. 67, 11677\u201311686 (2007).","journal-title":"Cancer Res."},{"key":"1002_CR28","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1093\/emboj\/cdg417","volume":"22","author":"CM Beausejour","year":"2003","unstructured":"Beausejour, C. M. et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 22, 4212\u20134222 (2003).","journal-title":"EMBO J."},{"key":"1002_CR29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.cell.2005.02.003","volume":"120","author":"J Campisi","year":"2005","unstructured":"Campisi, J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513\u2013522 (2005).","journal-title":"Cell"},{"key":"1002_CR30","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/nature08285","volume":"460","author":"J Utikal","year":"2009","unstructured":"Utikal, J. et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460, 1145\u20131148 (2009).","journal-title":"Nature"},{"key":"1002_CR31","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/nature08290","volume":"460","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Ink4\/Arf locus is a barrier for iPS cell reprogramming. Nature 460, 1136\u20131139 (2009).","journal-title":"Nature"},{"key":"1002_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-1-60761-999-4_11","volume":"698","author":"RC Lai","year":"2011","unstructured":"Lai, R. C., Choo, A. & Lim, S. K. Derivation and characterization of human ESC-derived mesenchymal stem cells. Methods Mol. Biol. 698, 141\u2013150 (2011).","journal-title":"Methods Mol. Biol."},{"key":"1002_CR33","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1073\/pnas.1015449108","volume":"108","author":"J Feng","year":"2011","unstructured":"Feng, J., Mantesso, A., De, B. C., Nishiyama, A. & Sharpe, P. T. Dual origin of mesenchymal stem cells contributing to organ growth and repair. Proc. Natl Acad. Sci. USA 108, 6503\u20136508 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1002_CR34","doi-asserted-by":"publisher","first-page":"8602","DOI":"10.1074\/jbc.M116.714915","volume":"291","author":"KD Copps","year":"2016","unstructured":"Copps, K. D., Hancer, N. J., Qiu, W. & White, M. F. Serine 302 phosphorylation of mouse insulin receptor substrate 1 (IRS1) is dispensable for normal insulin signaling and feedback regulation by hepatic S6 kinase. J. Biol. Chem. 291, 8602\u20138617 (2016).","journal-title":"J. Biol. Chem."},{"key":"1002_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.biocel.2015.03.006","volume":"64","author":"S Gao","year":"2015","unstructured":"Gao, S., Duan, C., Gao, G., Wang, X. & Yang, H. Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1\/S6K1 signaling. Int. J. Biochem. Cell Biol. 64, 25\u201333 (2015).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"1002_CR36","doi-asserted-by":"publisher","first-page":"21694","DOI":"10.1074\/jbc.M114.550038","volume":"289","author":"L Duan","year":"2014","unstructured":"Duan, L. et al. The prolyl peptidases PRCP\/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT. J. Biol. Chem. 289, 21694\u201321705 (2014).","journal-title":"J. Biol. Chem."},{"key":"1002_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.178","volume":"5","author":"OV Leontieva","year":"2014","unstructured":"Leontieva, O. V., Demidenko, Z. N. & Blagosklonny, M. V. Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium. Cell Death Dis. 5, e1214 (2014).","journal-title":"Cell Death Dis."},{"key":"1002_CR38","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1158\/0008-5472.CAN-03-2646","volume":"64","author":"EA Danna","year":"2004","unstructured":"Danna, E. A. et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 64, 2205\u20132211 (2004).","journal-title":"Cancer Res."},{"key":"1002_CR39","first-page":"1486","volume":"58","author":"BA Pulaski","year":"1998","unstructured":"Pulaski, B. A. & Ostrand-Rosenberg, S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58, 1486\u20131493 (1998).","journal-title":"Cancer Res."},{"key":"1002_CR40","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1245\/s10434-008-0037-5","volume":"15","author":"MJ Smith","year":"2008","unstructured":"Smith, M. J. et al. Mechanisms driving local breast cancer recurrence in a model of breast-conserving surgery. Ann. Surg. Oncol. 15, 2954\u20132964 (2008).","journal-title":"Ann. Surg. Oncol."},{"key":"1002_CR41","doi-asserted-by":"publisher","first-page":"20968","DOI":"10.1074\/jbc.M414696200","volume":"280","author":"JC Coffey","year":"2005","unstructured":"Coffey, J. C. et al. Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy. J. Biol. Chem. 280, 20968\u201320977 (2005).","journal-title":"J. Biol. Chem."},{"key":"1002_CR42","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1039\/c2nr30731f","volume":"4","author":"N Lei","year":"2012","unstructured":"Lei, N. et al. Therapeutic application of injectable thermosensitive hydrogel in preventing local breast cancer recurrence and improving incision wound healing in a mouse model. Nanoscale 4, 5686\u20135693 (2012).","journal-title":"Nanoscale"},{"key":"1002_CR43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/j.1478-3231.2010.02232.x","volume":"30","author":"CC Wong","year":"2010","unstructured":"Wong, C. C., Wong, C. M., Au, S. L. & Ng, I. O. RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N\u2019Rho move it. Liver Int. 30, 642\u2013656 (2010).","journal-title":"Liver Int."},{"key":"1002_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/156800910791054202","volume":"10","author":"S Micuda","year":"2010","unstructured":"Micuda, S., Rosel, D., Ryska, A. & Brabek, J. ROCK inhibitors as emerging therapeutic candidates for sarcomas. Curr. Cancer Drug Targets 10, 127\u2013134 (2010).","journal-title":"Curr. Cancer Drug Targets"},{"key":"1002_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-008-9170-7","volume":"28","author":"S Narumiya","year":"2009","unstructured":"Narumiya, S., Tanji, M. & Ishizaki, T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastas. Rev. 28, 65\u201376 (2009).","journal-title":"Cancer Metastas. Rev."},{"key":"1002_CR46","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ceb.2008.01.002","volume":"20","author":"MF Olson","year":"2008","unstructured":"Olson, M. F. Applications for ROCK kinase inhibition. Curr. Opin. Cell Biol. 20, 242\u2013248 (2008).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1002_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/stem.1224","volume":"31","author":"DJ Castro","year":"2013","unstructured":"Castro, D. J., Maurer, J., Hebbard, L. & Oshima, R. G. ROCK1 inhibition promotes the self-renewal of a novel mouse mammary cancer stem cell. Stem Cells 31, 12\u201322 (2013).","journal-title":"Stem Cells"},{"key":"1002_CR48","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/j.1474-9726.2011.00722.x","volume":"10","author":"T Chen","year":"2011","unstructured":"Chen, T. et al. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell 10, 908\u2013911 (2011).","journal-title":"Aging Cell"},{"key":"1002_CR49","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.4161\/cc.10.21.18128","volume":"10","author":"JA Menendez","year":"2011","unstructured":"Menendez, J. A., Vellon, L., Oliveras-Ferraros, C., Cufi, S. & Vazquez-Martin, A. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle 10, 3658\u20133677 (2011).","journal-title":"Cell Cycle"},{"key":"1002_CR50","doi-asserted-by":"crossref","unstructured":"Cornu, M., Albert, V. & Hall, M. N. mTOR in aging, metabolism, and cancer. Curr. Opin. Genet. Dev. 23, 53\u201362 (2013).","DOI":"10.1016\/j.gde.2012.12.005"},{"key":"1002_CR51","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nature08981","volume":"464","author":"M Kaeberlein","year":"2010","unstructured":"Kaeberlein, M. Lessons on longevity from budding yeast. Nature 464, 513\u2013519 (2010).","journal-title":"Nature"},{"key":"1002_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-61779-430-8_1","volume":"821","author":"T Weichhart","year":"2012","unstructured":"Weichhart, T. Mammalian target of rapamycin: a signaling kinase for every aspect of cellular life. Methods Mol. Biol. 821, 1\u201314 (2012).","journal-title":"Methods Mol. Biol."},{"key":"1002_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1098\/rstb.2010.0198","volume":"366","author":"MA McCormick","year":"2011","unstructured":"McCormick, M. A., Tsai, S. Y. & Kennedy, B. K. TOR and ageing: a complex pathway for a complex process. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366, 17\u201327 (2011).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"1002_CR54","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nature08221","volume":"460","author":"DE Harrison","year":"2009","unstructured":"Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392\u2013395 (2009).","journal-title":"Nature"},{"key":"1002_CR55","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1172\/JCI31377","volume":"117","author":"I Matushansky","year":"2007","unstructured":"Matushansky, I. et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J. Clin. Invest. 117, 3248\u20133257 (2007).","journal-title":"J. Clin. Invest."},{"key":"1002_CR56","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cell.2006.02.041","volume":"125","author":"BE Bernstein","year":"2006","unstructured":"Bernstein, B. E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315\u2013326 (2006).","journal-title":"Cell"},{"key":"1002_CR57","doi-asserted-by":"crossref","unstructured":"Sun, C. K. et al. Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers. Oncotarget 5, 3375\u20133385 (2014)","DOI":"10.18632\/oncotarget.1952"},{"key":"1002_CR58","doi-asserted-by":"crossref","unstructured":"Xiang, T. et al. Targeting the Akt\/mTOR pathway in Brca1-deficient cancers. Oncogene 30, 2443\u20132450 (2011).","DOI":"10.1038\/onc.2010.603"},{"key":"1002_CR59","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/ncb1867","volume":"11","author":"S Zeng","year":"2009","unstructured":"Zeng, S. et al. Telomere recombination requires the MUS81 endonuclease. Nat. Cell Biol. 11, 616\u2013623 (2009).","journal-title":"Nat. Cell Biol."}],"updated-by":[{"DOI":"10.1038\/s41419-022-05311-9","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"record-id":"40213"},{"DOI":"10.1038\/s41419-022-05311-9","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000}}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1002-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1002-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1002-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:10:20Z","timestamp":1671538220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1002-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":59,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-1002-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"10 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41419-022-05311-9","URL":"https:\/\/doi.org\/10.1038\/s41419-022-05311-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"915"}}